Daniel J. Becker - May 21, 2025 Form 4 Insider Report for ACELYRIN, Inc. (SLRN)

Role
Director
Signature
/s/ Eddie Kim, Attorney-in-fact
Stock symbol
SLRN
Transactions as of
May 21, 2025
Transactions value $
$0
Form type
4
Date filed
5/23/2025, 04:05 PM
Previous filing
Jul 19, 2024
Next filing
May 29, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Becker Daniel J. Director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS /s/ Eddie Kim, Attorney-in-fact 2025-05-23 0001752139

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRN Common Stock Disposed to Issuer -3K -100% 0 May 21, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRN Director Stock Option (right to buy) Disposed to Issuer -23.2K -100% 0 May 21, 2025 Common Stock 23.2K $18.00 Direct F2, F3
transaction SLRN Director Stock Option (right to buy) Disposed to Issuer -92.2K -100% 0 May 21, 2025 Common Stock 92.2K $4.46 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel J. Becker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F2 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F3 Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4 All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.